pcs Cost-effectiveness of PCSK9 Inhibitors for Heterozygous FH or ASCVD By dx.doi.org Published On :: Tue, 16 Aug 2016 15:00:00 +0000 Interview with Dhruv S. Kazi, MD, MSc, MS, author of Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease Full Article
